M
Mark R. Denison
Researcher at Vanderbilt University Medical Center
Publications - 145
Citations - 22620
Mark R. Denison is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Coronavirus & Viral replication. The author has an hindex of 57, co-authored 138 publications receiving 16782 citations. Previous affiliations of Mark R. Denison include Vanderbilt University & Thomas Jefferson University.
Papers
More filters
Journal ArticleDOI
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson,Evan J. Anderson,Nadine Rouphael,Paul C. Roberts,Mamodikoe Makhene,Rhea N. Coler,Michele Paine McCullough,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Nicole A. Doria-Rose,Kizzmekia S. Corbett,Kaitlyn M. Morabito,Sijy O’Dell,Stephen D. Schmidt,Phillip A. Swanson,Marcelino Padilla,John R. Mascola,Kathleen M. Neuzil,Hamilton Bennett,Wellington Sun,Etza Peters,Mat Makowski,Jim Albert,Kaitlyn Cross,Wendy Buchanan,Rhonda Pikaart-Tautges,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +32 more
TL;DR: The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Journal ArticleDOI
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Timothy P. Sheahan,Amy C. Sims,Sarah R. Leist,Alexandra Schäfer,John J. Won,Ariane J. Brown,Stephanie A. Montgomery,Alison Hogg,Darius Babusis,Michael O'neil Hanrahan Clarke,Jamie E. Spahn,Bauer Laura Elizabeth,Scott P. Sellers,Danielle P. Porter,Joy Y. Feng,Tomas Cihlar,Robert Jordan,Mark R. Denison,Ralph S. Baric +18 more
TL;DR: Remdesivir (RDV) has superior anti-MERS activity in vitro and in vivo compared to combination therapy with lopinavir, ritonavir and interferon beta and reduces severe lung pathology.
Journal ArticleDOI
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan,Amy C. Sims,Rachel L. Graham,Vineet D. Menachery,Lisa E. Gralinski,James Brett Case,Sarah R. Leist,Krzysztof Pyrc,Joy Y. Feng,Iva Trantcheva,Roy Bannister,Yeojin Park,Darius Babusis,Michael O. Clarke,Richard L. Mackman,Jamie E. Spahn,Christopher A. Palmiotti,Dustin Siegel,Adrian S. Ray,Tomas Cihlar,Robert Jordan,Mark R. Denison,Ralph S. Baric +22 more
TL;DR: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses in vitro and in vivo and may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.
Journal ArticleDOI
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
Maria L. Agostini,Erica L. Andres,Amy C. Sims,Rachel L. Graham,Timothy P. Sheahan,Xiaotao Lu,Everett Clinton Smith,Everett Clinton Smith,James Brett Case,Joy Y. Feng,Robert Jordan,Adrian S. Ray,Tomas Cihlar,Dustin Siegel,Richard L. Mackman,Michael O'neil Hanrahan Clarke,Ralph S. Baric,Mark R. Denison +17 more
TL;DR: It is shown that GS-5734 inhibits murine hepatitis virus (MHV) with similar 50% effective concentration values (EC50) as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS- coV) and that resistance can be overcome with increased, nontoxic concentrations of GS- 5734, further supporting the development of GS -5734 as a broad-spectrum therapeutic to protect against contemporary and emerging CoVs.
Journal ArticleDOI
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Evan J. Anderson,Nadine Rouphael,Alicia T. Widge,Lisa A. Jackson,Paul C. Roberts,Mamodikoe Makhene,James D. Chappell,Mark R. Denison,Laura J. Stevens,Andrea J. Pruijssers,Adrian B. McDermott,Britta Flach,Bob C. Lin,Nicole A. Doria-Rose,Sijy O'Dell,Stephen D. Schmidt,Kizzmekia S. Corbett,Phillip A. Swanson,Marcelino Padilla,Kathy M. Neuzil,Hamilton Bennett,Brett A. Leav,Mat Makowski,Jim Albert,Kaitlyn Cross,Venkata Viswanadh Edara,Katharine Floyd,Mehul S. Suthar,David R. Martinez,Ralph S. Baric,Wendy Buchanan,Catherine J. Luke,Varun K Phadke,Christina A. Rostad,Julie E. Ledgerwood,Barney S. Graham,John H. Beigel +36 more
TL;DR: The phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein in healthy adults found it induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100- μg dose in a phase 3 vaccine trial.